Cara Therapeutics Inc CARA

NAS: CARA | ISIN: US1407551092 15/04/2025

5,320 USD (-4,14%)

(-4,14%) 15/04/2025

Grafiek Cara Therapeutics Inc

Grafiek Cara Therapeutics Inc

1 dag1d -4,14%
1 week1w 0,00%
1 maand1m 7,69%
3 maanden3m 11,30%
6 maanden6m 1.691,25%
1 jaar1j 601,29%
5 jaar5j -62,64%

Cara Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

3 juni 2023 · Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 · Persbericht

18 mei 2023 · Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus · Persbericht

10 oktober 2022 · SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics · Persbericht

11 juni 2021 · SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics · Persbericht

6 april 2021 · Cara Therapeutics Set to Join S&P SmallCap 600 · Persbericht

8 maart 2021 · Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus · Persbericht

25 februari 2021 · Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results · Persbericht

18 februari 2021 · Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 · Persbericht

6 januari 2021 · Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Cara Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.caratherapeutics.com

Hoofdzetel: Stamford, Connecticut Verenigde Staten

CEO: Derek Chalmers

Werknemers: 97

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe